Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Reduction in Vaccine-Type HPV Prevalence

J Infect Dis; ePub 2016 Nov 7; Berenson, et al

Publish date:: November 16, 2016

The proportion of young women in the US completing the human papillomavirus vaccine doubled between 2009 and 2012, according to a recent study, which evaluated the prevalence of vaccine-type HPV strains among young women in national datasets from 2009-2010 and 2011-2012. Researchers found:

Among females aged 18 to 26 years, the prevalence of vaccine-type HPV decreased markedly over a short interval from 15.4% in 2009-2019 to 8.5% in 2011-2012.
The prevalence of high-risk vaccine-type HPV decreased from 13.1% to 6.5%.
Reductions in HPV-related diseases are likely to follow.

Citation:

Berenson AB, Laz TH, Rahman M. Reduction in vaccine-type human papillomavirus prevalence among adult females in the United States, 2009-2012. [Published online ahead of print November 7, 2016]. J Infect Dis. doi:10.1093/infdis/jiw515.

This Week's Must Reads

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Three genes could predict congenital Zika infection susceptibility,

‘Excellent short-term outcomes’ seen in HCV+ liver transplants to HCV– recipients,

Must Reads in Vaccines

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

Flu vaccine significantly cuts pediatric hospitalizations,

HPV vaccination remains below Healthy People goals despite increases,

COVID-19 may discourage pediatric flu vaccination,

Shingrix effective in older adults with preexisting immune-mediated disorders,